A three-dose course of AstraZeneca’s COVID-19 vaccine is effective against the rapidly-spreading Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
The study, which has not yet been published in a medical journal, showed that levels of omicron antibodies after receiving the third booster dose were higher than those of those who had contracted coronavirus and recovered normally.
After a three-dose course of the vaccine, the neutralizing levels against Omicron were similar to those of the anti-delta mutant after two doses, the company added.